Latest Market Sentiment News

Tempest Minerals has completed a pro-rata entitlement offer, raising over $600,000 to fund exploration in Western Australia, though a significant shortfall remains to be allocated.

Northern Minerals Limited has responded to ASX inquiries about recent unusual trading activity, confirming no undisclosed information but highlighting ongoing project developments and market factors influencing its share price.

Lightning Minerals has advanced its lithium exploration at the Dundas project in Western Australia through a detailed infill soil sampling program, revealing promising lithium concentrations that refine existing targets.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Blackstone Minerals has clarified that its recent share price jump is driven by market anticipation of its merger with IDM International, with no undisclosed information influencing trading.

Donaco International has updated the timeline for its acquisition by On Nut Road Limited, pushing key dates into August due to valuation and legal review delays. Shareholders await the next steps in this protracted takeover process.

Sparc Technologies has successfully closed its Share Purchase Plan, raising more than double its initial target, signaling strong shareholder confidence as it advances its green hydrogen and graphene projects.

Thunderbird Resources has entered a strategic option agreement with Mustang Energy, enabling Mustang to acquire up to 80% of two promising uranium projects in Canada’s Athabasca Basin while Thunderbird sharpens its focus on gold-antimony assets in New South Wales.

CAQ Holdings Limited has resumed trading on the ASX following the release of its annual report and an update on a new debt facility and company restructure.

REA Group has confirmed it is under investigation by the ACCC concerning its subscription offerings, signaling potential regulatory scrutiny for the property tech giant.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

Nufarm Limited confirms its half-year earnings align closely with analyst expectations despite a late-stage $16 million inventory valuation adjustment. The company maintains compliance with ASX disclosure rules amid market scrutiny.